FucT-VI Inhibitors

Chemical inhibitors of FucT-VI operate through diverse mechanisms to impede its fucosyltransferase activity. 2F-Peracetyl-fucose functions as a competitive inhibitor; it closely resembles the natural fucose substrate that FucT-VI utilizes for glycan modifications. By binding to the active site of FucT-VI, this analog prevents the proper transfer of fucose to oligosaccharide chains on glycoproteins and glycolipids. Similarly, GDP-D-mannose competes with the natural donor substrate GDP-fucose, thereby occupying the enzyme's substrate binding site and lowering its functional activity. On the other hand, Brefeldin A does not compete with the fucose substrate but disrupts the structure of the Golgi apparatus, where FucT-VI is localized and operates, which in turn affects the enzyme's access to its glycoprotein and glycolipid substrates.

Other chemicals target the upstream processes that provide substrates for FucT-VI. Swainsonine and Kifunensine inhibit specific mannosidases, leading to an accumulation of high-mannose glycans and a subsequent decrease in complex glycan structures that serve as substrates for FucT-VI. Benzyl-α-GalNAc impedes O-glycan synthesis, a preliminary step in the biosynthetic pathway that feeds into FucT-VI's substrate pool. Castanospermine and Deoxynojirimycin target glucosidases, which are responsible for N-glycan maturation; their inhibition results in improperly folded glycoproteins that FucT-VI cannot effectively fucosylate. Deoxymannojirimycin plays a similar role by inhibiting mannosidases, limiting the maturation of glycan structures. Tunicamycin and Nojirimycin also hinder the maturation of N-linked glycans, the former by inhibiting the formation of dolichol-linked oligosaccharides necessary for N-linked glycosylation, and the latter by inhibiting glucosidases. These disruptions lead to a reduction in the availability of correctly folded glycoprotein substrates required for FucT-VI's fucosylation activity, effectively diminishing the enzyme's function.